Wolff Wiese Magana’s Intellia Therapeutics NTLA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.02K Hold
60
﹤0.01% 915
2026
Q1
$770 Hold
60
﹤0.01% 890
2025
Q4
$540 Hold
60
﹤0.01% 885
2025
Q3
$1.04K Hold
60
﹤0.01% 844
2025
Q2
$563 Hold
60
﹤0.01% 898
2025
Q1
$427 Hold
60
﹤0.01% 930
2024
Q4
$700 Sell
60
-70
-54% -$1.09K ﹤0.01% 853
2024
Q3
$2.67K Hold
130
﹤0.01% 688
2024
Q2
$2.91K Hold
130
﹤0.01% 498
2024
Q1
$3.58K Hold
130
﹤0.01% 440
2023
Q4
$3.96K Sell
130
-30
-19% -$862 ﹤0.01% 406
2023
Q3
$5.06K Sell
160
-100
-38% -$3.88K ﹤0.01% 432
2023
Q2
$10.6K Hold
260
0.01% 339
2023
Q1
$9.69K Sell
260
-70
-21% -$2.75K 0.01% 353
2022
Q4
$11.5K Sell
330
-55
-14% -$2.62K 0.01% 321
2022
Q3
$22K Hold
385
0.02% 360
2022
Q2
$20K Sell
385
-8
-2% -$406 0.01% 399
2022
Q1
$29K Sell
393
-993
-72% -$84.1K 0.02% 353
2021
Q4
$164K Sell
1,386
-78
-5% -$9.77K 0.11% 147
2021
Q3
$196K Buy
1,464
+259
+21% +$39.2K 0.14% 129
2021
Q2
$195K Buy
+1,205
New +$93.8K 0.14% 126

Other funds holding NTLA

Wolff Wiese Magana's NTLA Position: Q2 2026 in Review

Wolff Wiese Magana held its Intellia Therapeutics (NTLA) position steady in Q2 2026 at 60 shares worth $1.02K. The position accounts for ﹤0.01% of the portfolio, ranked #915.

Wolff Wiese Magana first reported a position in NTLA in Q2 2021 and has held it in 21 quarters since. The position peaked at $196K in Q3 2021. 77 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Wolff Wiese Magana held 60 shares of Intellia Therapeutics worth $1.02K as of Q2 2026.
  • Wolff Wiese Magana left its Intellia Therapeutics share count unchanged in Q2 2026.
  • Intellia Therapeutics made up ﹤0.01% of Wolff Wiese Magana's portfolio in Q2 2026, its #915 holding.
  • Wolff Wiese Magana first reported a position in Intellia Therapeutics in Q2 2021 and has held it in 21 quarters since.
  • Wolff Wiese Magana's Intellia Therapeutics position peaked at $196K in Q3 2021.
  • 77 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Wolff Wiese Magana's 13F filing for Q2 2026, filed 13 Jul 2026.